AbbVie (NYSE:ABBV) Announces Earnings Results, Beats Estimates By $0.05 EPS

AbbVie (NYSE:ABBV) released its earnings results on Friday. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.60 by $0.05, FiscalAI reports. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.During the same quarter last year, the company earned $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie updated its Q3 2026 guidance to 3.840-3.880 EPS.

Here are the key takeaways from AbbVie’s conference call:

• Strong second-quarter execution lifted revenue 10.2% to nearly $17 billion and adjusted EPS to $3.65, beating expectations. AbbVie raised full-year revenue guidance by $300 million to approximately $67.6 billion and increased adjusted EPS guidance to $13.87–$14.07.
• Immunology and neuroscience remained key growth engines, led by SKYRIZI sales of $5.5 billion, up 24%, and RINVOQ sales above $2.5 billion, up 23.7%; neuroscience revenue grew about 20%. Management expects further SKYRIZI momentum from a potential U.S. approval of subcutaneous Crohn’s induction dosing later this year.
• AbbVie highlighted multiple pipeline and business-development catalysts, including the planned Apogee acquisition, European approvals for RINVOQ in vitiligo and alopecia areata, expected U.S. approval decisions for tavapadone, and progress across oncology ADCs and immunology combinations.
• The Apogee transaction is expected to close in the third quarter and will dilute 2026 EPS by an estimated $0.14, while increasing R&D spending and interest expense. AbbVie plans to use interim financing and issue long-term debt, targeting a return to two-times net leverage within two to three years.
• Oncology revenue declined 2.4% operationally, primarily due to expected IMBRUVICA pressure from IRA pricing and competition, while aesthetics revenue fell 0.9% as JUVÉDERM sales declined 6.6%. HUMIRA sales also fell 36.1% because of biosimilar competition.

AbbVie Stock Down 2.4%

Shares of ABBV stock traded down $6.08 during trading hours on Friday, reaching $251.33. 7,251,186 shares of the stock traded hands, compared to its average volume of 7,040,380. AbbVie has a 1-year low of $187.62 and a 1-year high of $267.47. The business has a fifty day moving average price of $238.39 and a 200 day moving average price of $223.86. The firm has a market capitalization of $444.05 billion, a PE ratio of 123.81, a PEG ratio of 0.87 and a beta of 0.30.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s payout ratio is currently 340.89%.

Hedge Funds Weigh In On AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC acquired a new position in AbbVie during the fourth quarter valued at $28,000. Imprint Wealth LLC boosted its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the 4th quarter valued at about $31,000. Quarry LP purchased a new position in AbbVie during the 3rd quarter valued at about $41,000. Finally, Jessup Wealth Management Inc acquired a new position in shares of AbbVie in the 4th quarter valued at about $42,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABBV. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wells Fargo & Company increased their target price on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $269.29.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.